Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice
- PMID: 15574772
- DOI: 10.1158/0008-5472.CAN-04-2760
Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice
Abstract
Tumor growth, tumor angiogenesis, and vascular endothelial growth factor (VEGF)-specific angiogenesis are all enhanced in beta(3)-integrin-null mice. Furthermore, endothelial cells isolated from beta(3)-null mice show elevated levels of Flk1 (VEGF receptor 2) expression, suggesting that beta(3)-integrin can control the amplitude of VEGF responses by controlling Flk1 levels or activity. We now show that Flk1 signaling is required for the enhanced tumor growth and angiogenesis seen in beta(3)-null mice. Moreover, beta(3)-null endothelial cells exhibit enhanced migration and proliferation in response to VEGF in vitro, and this phenotype requires Flk1 signaling. Upon VEGF stimulation, beta(3)-null endothelial cells exhibit higher levels of phosphorylated Flk1 and extracellular-related kinases 1 and 2 than wild-type endothelial cells. Furthermore, signaling via ERK1/2 is required to mediate the elevated responses to VEGF observed in beta(3)-null endothelial cells and aortic rings in vitro. These data confirm that VEGF signaling via Flk1 is enhanced in beta(3)-integrin-deficient mice and suggests that this increase may mediate the enhanced angiogenesis and tumor growth observed in these mice in vivo.
Similar articles
-
Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins.Nat Med. 2002 Jan;8(1):27-34. doi: 10.1038/nm0102-27. Nat Med. 2002. PMID: 11786903
-
Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.Cancer Res. 2004 May 15;64(10):3586-92. doi: 10.1158/0008-5472.CAN-03-2673. Cancer Res. 2004. PMID: 15150116
-
Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability.Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2108-14. doi: 10.1161/01.ATV.0000143857.27408.de. Epub 2004 Sep 2. Arterioscler Thromb Vasc Biol. 2004. PMID: 15345507
-
Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome.Verh K Acad Geneeskd Belg. 2005;67(4):229-76. Verh K Acad Geneeskd Belg. 2005. PMID: 16334858 Review.
-
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?Nat Rev Cancer. 2002 Nov;2(11):826-35. doi: 10.1038/nrc925. Nat Rev Cancer. 2002. PMID: 12415253 Review. No abstract available.
Cited by
-
Glanzmann thrombasthenia.Orphanet J Rare Dis. 2006 Apr 6;1:10. doi: 10.1186/1750-1172-1-10. Orphanet J Rare Dis. 2006. PMID: 16722529 Free PMC article. Review.
-
Dual effects of β3 integrin subunit expression on human pancreatic cancer models.Cell Oncol (Dordr). 2011 Aug;34(4):393-405. doi: 10.1007/s13402-011-0039-3. Epub 2011 May 31. Cell Oncol (Dordr). 2011. PMID: 21626402
-
The angiogenic response is dictated by beta3 integrin on bone marrow-derived cells.J Cell Biol. 2008 Dec 15;183(6):1145-57. doi: 10.1083/jcb.200802179. J Cell Biol. 2008. PMID: 19075116 Free PMC article.
-
Absence of beta3 integrin accelerates early skeletal repair.J Orthop Res. 2010 Jan;28(1):32-7. doi: 10.1002/jor.20955. J Orthop Res. 2010. PMID: 19637214 Free PMC article.
-
Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances.Adv Drug Deliv Rev. 2013 Jan;65(1):121-38. doi: 10.1016/j.addr.2012.09.041. Epub 2012 Sep 29. Adv Drug Deliv Rev. 2013. PMID: 23026636 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous